Literature DB >> 19364253

Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.

Dan-Arin Silasi1, Ayesha B Alvero, Thomas J Rutherford, David Brown, Gil Mor.   

Abstract

BACKGROUND: Phenoxodiol is a synthetic derivative of the naturally occurring plant isoflavone genistein. The observation that an inverse relationship exists between dietary intake of isoflavones and cancer incidence has led to the evaluation of these compounds in cancer therapy.
OBJECTIVE: This article reviews the mechanisms of action of phenoxodiol and the completed and ongoing clinical studies evaluating this drug. RESULTS/
CONCLUSIONS: By altering the chemical structure of genistein, the new compound phenoxodiol showed increased anticancer activity without any increase in toxicity. In addition to its direct cytotoxic activity against different cancers, phenoxodiol sensitizes chemoresistant ovarian cancer cells to platinum and taxane drugs, as well as gemcitabine and topotecan. The US Food and Drug Administration has granted 'fast track' status to the development of phenoxodiol as chemosensitizer for platinum and taxane drugs used in the treatment of recurrent ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364253     DOI: 10.1517/14656560902837980

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  16 in total

Review 1.  Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.

Authors:  Min Shen; Tak Hang Chan; Q Ping Dou
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

2.  Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I).

Authors:  Sze Chern Lim; Kirstyn T Carey; Matthew McKenzie
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 3.  Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.

Authors:  Koh Miura; Wataru Fujibuchi; Kazuyuki Ishida; Takeshi Naitoh; Hitoshi Ogawa; Toshinori Ando; Nobuki Yazaki; Kazuhiro Watanabe; Sho Haneda; Chikashi Shibata; Iwao Sasaki
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

4.  The continuing search for antitumor agents from higher plants.

Authors:  Li Pan; Heebyung Chai; A Douglas Kinghorn
Journal:  Phytochem Lett       Date:  2010-03-12       Impact factor: 1.679

5.  Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines.

Authors:  Simon Mahoney; Frank Arfuso; Pierra Rogers; Susan Hisheh; David Brown; Michael Millward; Arun Dharmarajan
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

6.  Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.

Authors:  Yefim Manevich; Leticia Reyes; Carolyn D Britten; Danyelle M Townsend; Kenneth D Tew
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

7.  Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.

Authors:  Chen Yao; Sujia Wu; Dong Li; Huimin Ding; Zuyu Wang; Yongjiang Yang; Shichang Yan; Zhangping Gu
Journal:  Mol Oncol       Date:  2012-05-05       Impact factor: 6.603

Review 8.  Phytochemicals in cancer prevention and therapy: truth or dare?

Authors:  Maria Russo; Carmela Spagnuolo; Idolo Tedesco; Gian Luigi Russo
Journal:  Toxins (Basel)       Date:  2010-03-31       Impact factor: 4.546

9.  Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3PT platinum-resistant human ovarian cancer cells.

Authors:  Yan-Ying Zhong; He-Ping Chen; Bu-Zhen Tan; Hai-Hong Yu; Xiao-Shan Huang
Journal:  Oncol Lett       Date:  2013-08-12       Impact factor: 2.967

10.  NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.

Authors:  Koba Kiknavelidze; Mikheil Shavdia; Nana Chikhladze; Lia Abshilava; Marinella Messina; Gisela Mautner; Graham Kelly
Journal:  Curr Ther Res Clin Exp       Date:  2021-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.